Remission and recovery in the treatment for adolescents with depression study (TADS): Acute and long-term outcomes

Journal of the American Academy of Child and Adolescent Psychiatry

Volumn 48, Issue 2, 2009, Pages 186-195

  Kennard, Betsy D ^a,h   Silva, Susan G ^b   Tonev, Simon ^b   Rohde, Paul ^c   Hughes, Jennifer L ^a   Vitiello, Benedetto ^d   Kratochvil, Christopher J ^e   Curry, John F ^f   Emslie, Graham J ^a   Reinecke, Mark ^g   March, John ^f  

^a UNIVERSITY OF TEXAS   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c OREGON RESEARCH INSTITUTE   (United States)

^d NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^e UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

^g NORTHWESTERN UNIVERSITY   (United States)

^h UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Adolescent depression; Recovery; Remission; Residual symptoms

Indexed keywords

FLUOXETINE;

ADOLESCENT; ARTICLE; CLINICAL TRIAL; COGNITIVE THERAPY; CONTROLLED CLINICAL TRIAL; CONVALESCENCE; DEPRESSION; DRUG DOSE INCREASE; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROBABILITY; REMISSION; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 60449098712     PISSN: 08908567     EISSN: 15275418     Source Type: Journal    
DOI: 10.1097/CHI.0b013e31819176f9     Document Type: Article

References (41)

1. Birmaher B, Brent D. Practice parameters for the assessment and treatment of children and adolescents with depressive disorders. J Am Acad Child Adolesc Psychiatry. 1998;37:63S-83S.
2. Park RJ, Goodyer IM. Clinical guidelines for depressive disorders in childhood and adolescence. Eur Child Adolesc Psychiatry. 2000;9: 147-161.
3. Brent DA, Holder D, Kolko D et al. A clinical psychotherapy trial for adolescent depression comparing cognitive, family, and supportive therapy. Arch Gen Psychiatry. 1997;54:877-885.
4. Birmaher B, Brent DA, Kolko D et al. Clinical outcome after short-term psychotherapy for adolescents with major depressive disorder. Arch Gen Psychiatry. 2000;57:29-36.
5. Cheung AH, Emslie GJ, Mayes TL. Review of the efficacy and safety of antidepressants in youth depression. J Child Psychol Psychiatry. 2005;46: 735-754.
6. Kennard B, Silva S, Vitiello B et al. Remission and residual symptoms after short-term treatment in the Treatment of Adolescents with depression study (TADS). J Am Acad Child Adolesc Psychiatry. 2006; 45:1404-1411.
7. Poznanski E, Mokros H. Children's Depression Rating Scale-Revised (CDRS-R). Los Angeles: Western Psychological Services; 1996.
8. Brent DA. Glad for what TADS adds, but many TADS grads still sad. J Am Acad Child Adolesc Psychiatry. 2006;45:1461-1464.
9. Kocsis JH, Friedman RA, Markowitz JC et al. Maintenance therapy for chronic depression: a controlled clinical trial of desipramine. Arch Gen Psychiatry. 1996;53:769-774.
10. Koran LM, Gelenberg AJ, Kornstein SG et al. Sertraline versus imipramine to prevent relapse in chronic depression. J Affect Disord. 2001;65: 27-36.
11. Kocsis JH, Rush AJ, Markowitz JC et al. Continuation treatment of chronic depression: a comparison of nefazodone, cognitive behavioral analysis system of psychotherapy, and their combination. Psychopharmacol Bull. 2003;37:73-87.
12. Rush AJ, Kraemer HC, Sackeim HA et al. Report by the ACNP Task Force on response and remission in major depressive disorder. Neuropsychopharmacology. 2006;31:1841-1853.
13. Clarke GN, Rohde P, Lewinsohn PM, Hops H, Seeley JR. Cognitive-behavioral treatment of adolescent depression: efficacy of acute group treatment and booster sessions. J Am Acad Child Adolesc Psychiatry. 1999; 38:272-279.
14. Kovacs M. Presentation and course of major depressive disorder during childhood and later years of the lifespan. J Am Acad Child Adolesc Psychiatry. 1996;35:705-715.
15. Kovacs M, Obrosky S, Gatsonis C, Richards C. First-episode major depressive and dysthymic disorder in childhood: Clinical and sociodemographic factors in recovery. J Am Acad Child Adolesc Psychiatry. 1997;36:777-784.
16. Cornwall P, Scott J. Partial remission in depressive disorders. Acta Psychiatr Scand. 1997;95:265-271.
17. Judd L, Akiskal H, Maser J et al. Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. J Affect Disord. 1998;50:97-108.
18. Keller M. Remission versus response: the new gold standard of antidepressant care. J Clin Psychiatry. 2004;65:53-59.
19. Faravelli C, Ambonetti A, Pallanti S, Pazzagli A. Depressive relapses and incomplete recovery from index episode. Am J Psychiatry. 1986;143: 888-891.
20. Fava G, Grandi S, Zielezny M, Canestrari R, Morphy M. Cognitive behavioral treatment of residual symptoms in primary depressive disorder. Am J Psychiatry. 1994;151:1295-1299.
21. Paykel E, Ramana R, Cooper Z, Hayhurst H, Kerr J, Barocka A. Residual symptoms after partial remission: an important outcome in depression. Psychol Med. 1995;25:1171-1180.
22. Simons A, Murphy G, Levine J, Wetzel R. Cognitive therapy and pharmacotherapy for depression: sustained improvement over one year. Arch Gen Psychiatry. 1986;43:43-48.
23. Thase M, Simons A, McGeary J et al. Relapse after cognitive behavior therapy of depression: potential implications for longer courses of treatment. Am J Psychiatry. 1992;149:1046-1052.
24. Guy W. ECDEU Assessment Manual for Psychopharmacology. 2nd ed. (DHEW publication no. ABM 76-388). Washington: US Government Printing Office; 1976.
25. Emslie GJ, Kennard BD, Mayes TL et al. Fluoxetine versus placebo in preventing relapse of major depression in children and adolescents. Am J Psychiatry. 2008;165:459-467.
26. Brent DA, Birmaher B, Kolko D, Baugher M, Bridge J. Subsyndromal depression in adolescents after a brief psychotherapy trial; course and outcome. J Affect Disord. 2001;63:51-58.
27. Fergusson DM, Horwood LJ, Ridder EM, Beautrais AL. Subthreshold depression in adolescence and mental health outcomes in adulthood. Arch Gen Psychiatry. 2005;62:66-72.
28. Lewinsohn PM, Solomon A, Seeley JR, Zeiss A. Clinical implications of "subthreshold" depressive symptoms. J Abnorm Psychol. 2000;109: 345-351.
29. TADS. The Treatment for Adolescents With Depression Study (TADS): rationale, design, and methods. J Am Acad Child Adolesc Psychiatry. 2003;42:531-542.
30. March J, Silva S, Vitiello B. The TADS Team. The Treatment for Adolescents with Depression Study (TADS): methods and message at 12 weeks. J Am Acad Child Adolesc Psychiatry. 2006;45:1393-1403.
31. TADS. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents with Depression Study (TADS) randomized controlled trial. JAMA. 2004;292:807-820.
32. TADS. The Treatment for Adolescents with Depression Study (TADS): long-term effectiveness and safety outcomes. Arch Gen Psychiatry. 2007; 64:1132-1143.
33. TADS. The Treatment for Adolescents with Depression Study (TADS): demographics and clinical characteristics. J Am Acad Child Adolesc Psychiatry. 2005;44:28-40.
34. Kaufman J, Birmaher B, Brent D et al. Schedule for Affective Disorders and Schizophrenia for School-Age Children Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry. 1997;36:980-988.
35. Ascher BH, Farmer EMZ, Burns BJ, Angold A. The Child and Adolescent Services Assessment (CASA): description and psychometrics. J Emot Behav Disord. 1996;4:12-20.
36. Emslie G, Rush A, Weinberg W et al. A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry. 1997;54:1031-1037.
37. Emslie GJ, Heiligenstein JH, Wagner KD et al. Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial. J Am Acad Child Adolesc Psychiatry. 2002; 41:1205-1215.
38. Wagner K, Robb A, Findling R, Jin J, Guderrez M, Heydom W. A randomized, placebo-controlled trial of citalopram for the treatment of major depression in children and adolescents. Am J Psychiatry. 2004; 161:1079-1083.
39. Rush AJ, Trivedi MH, Wisniewski SR et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163:1905-1917.
40. Hollon SD, DeRubeis RJ, Shelton RC et al. Prevention of relapse following cognitive therapy vs. medications in moderate to severe depression. Arch Gen Psychiatry. 2005:62:417-422.
41. Weersing VR, Weisz JR. Community clinic treatment of depressed youth: benchmarking usual care against CBT clinical trials. J Consult Clin Psychol. 2002;70:299-310.